Venetoclax with azacitidine disrupts energy metabolism and targets leukemia stem cells in patients with acute myeloid leukemia

AMPK/FIS1-Mediated Mitophagy Is Required for Self-Renewal of Human AML Stem Cells

(2018) Shanshan Pei et al.   Cell Stem Cell

Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study

(2018) Courtney D DiNardo et al.   LANCET ONCOLOGY

Molecularly targeted drug combinations demonstrate selective effectiveness for myeloid- and lymphoid-derived hematologic malignancies

(2017) Stephen E. Kurtz et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Evolution of acute myelogenous leukemia stem cell properties after treatment and progression

(2016) T.-C. Ho et al.   BLOOD

Rational Design of a Parthenolide-based Drug Regimen That Selectively Eradicates Acute Myelogenous Leukemia Stem Cells

(2016) Shanshan Pei et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

A 17-gene stemness score for rapid determination of risk in acute leukaemia

(2016) Stanley W. K. Ng et al.   NATURE

Assessment of Minimal Residual Disease in Standard-Risk AML

(2016) Adam Ivey et al.   NEW ENGLAND JOURNAL OF MEDICINE

Efficacy and Biological Correlates of Response in a Phase II Study of Venetoclax Monotherapy in Patients with Acute Myelogenous Leukemia

(2016) M. Konopleva et al.   Cancer Discovery

Three-minute method for amino acid analysis by UHPLC and high-resolution quadrupole orbitrap mass spectrometry

(2015) Travis Nemkov et al.   AMINO ACIDS

AML cells have low spare reserve capacity in their respiratory chain that renders them susceptible to oxidative metabolic stress

(2015) S. Sriskanthadevan et al.   BLOOD

International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts

(2015) H. Dombret et al.   BLOOD

Inhibition of the Mitochondrial Protease ClpP as a Therapeutic Strategy for Human Acute Myeloid Leukemia

(2015) Alicia Cole et al.   CANCER CELL

Isocitrate dehydrogenase 1 and 2 mutations induce BCL-2 dependence in acute myeloid leukemia

(2015) Steven M Chan et al.   NATURE MEDICINE

Searching for Drug Synergy in Complex Dose–Response Landscapes Using an Interaction Potency Model

(2015) Bhagwan Yadav et al.   Computational and Structural Biotechnology Journal

Targeting acute myeloid leukemia stem cells: a review and principles for the development of clinical trials

(2014) D. A. Pollyea et al.   HAEMATOLOGICA

BCL-2 family proteins as 5-Azacytidine-sensitizing targets and determinants of response in myeloid malignancies

(2014) J M Bogenberger et al.   LEUKEMIA

Ex vivoactivity of BCL-2 family inhibitors ABT-199 and ABT-737 combined with 5-azacytidine in myeloid malignancies

(2014) James M. Bogenberger et al.   LEUKEMIA & LYMPHOMA

Identification of pre-leukaemic haematopoietic stem cells in acute leukaemia

(2014) Liran I. Shlush et al.   NATURE

Oncogene ablation-resistant pancreatic cancer cells depend on mitochondrial function

(2014) Andrea Viale et al.   NATURE

BCL-2 Inhibition Targets Oxidative Phosphorylation and Selectively Eradicates Quiescent Human Leukemia Stem Cells

(2013) Eleni D. Lagadinou et al.   Cell Stem Cell

viSNE enables visualization of high dimensional single-cell data and reveals phenotypic heterogeneity of leukemia

(2013) El-ad David Amir et al.   NATURE BIOTECHNOLOGY

ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets

(2013) Andrew J Souers et al.   NATURE MEDICINE

Selective BCL-2 Inhibition by ABT-199 Causes On-Target Cell Death in Acute Myeloid Leukemia

(2013) R. Pan et al.   Cancer Discovery

Inhibition of Mitochondrial Translation as a Therapeutic Strategy for Human Acute Myeloid Leukemia

(2011) Marko Škrtić et al.   CANCER CELL

Stem cell gene expression programs influence clinical outcome in human leukemia

(2011) Kolja Eppert et al.   NATURE MEDICINE

Human acute myelogenous leukemia stem cells are rare and heterogeneous when assayed in NOD/SCID/IL2Rγc-deficient mice

(2010) Jean-Emmanuel Sarry et al.   JOURNAL OF CLINICAL INVESTIGATION

Mechanisms of Antileukemic Activity of the Novel Bcl-2 Homology Domain-3 Mimetic GX15-070 (Obatoclax)

(2008) M. Konopleva et al.   CANCER RESEARCH